Main navigation

Vol 36, (9) 673–784

Osteoarthritis management of the knee - Treatment options post the NSAID cardiotoxicity controversy

Jan Gartlan MBBS(Hons), BMedSci, FRACGP, is a PhD scholar, Menzies Research Institute, University of Tasmania.

Mark Nelson MBBS(Hons), MFM, FRACGP, FAFPHM, PhD, is Chair, Discipline of General Practice, School of Medicine, University of Tasmania, and Senior Fellow, Menzies Research Institute.

Graeme Jones MBBS(Hons), FRACP, MMedSc, MD, FAFPHM, is Head, Musculoskeletal Unit, Menzies Research Institute, Tasmania.

Osteoarthritis (OA) is a common, chronic musculoskeletal condition affecting at least 1.2 million Australians. It is the leading cause of pain and disability in the community, particularly affecting women, and the seventh most commonly managed condition in general practice. Although the pathogenesis is not fully understood, the factors involved include biomechanical stresses affecting the articular cartilage and subchondral bone, biochemical changes in the articular cartilage and genetic susceptibility. Knee and hip joints usually cause the most morbidity. Patients with OA complain of pain which typically worsens with weight bearing and is relieved with rest. They may also have joint stiffness, particularly after a period of inactivity.

Publication Date: 3 September 2007
Authorised By: Australian family physician